This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction
by Zacks Equity Research
Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.
Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara
by Zacks Equity Research
Eli Lilly and Company (LLY) announced superior efficacy in a head-to-head study evaluating its marketed drug, Taltz (ixekizumab) versus with Johnson & Johnson???s Stelara (ustekinumab) in patients with moderate-to-severe plaque.
Novartis (NVS) Reports Positive Data on Biosimilar Humira
by Zacks Equity Research
Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.
Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Ophthotech Corporation (OPHT) reported fourth-quarter 2016 loss of $1.86 per share, wider than both the Zacks Consensus Estimate of a loss of $1.64 and the year-ago loss of $1.02.
Medicines Company (MDCO) Q4 Loss Narrower than Expected
by Zacks Equity Research
The Medicines (MDCO) reported a loss of $1.29 per share (including the impact of share-based compensation expenses) in the fourth quarter of 2016, narrower than Zacks Consensus Estimate of a loss of $1.43.
Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) is expected to report fourth-quarter 2016 results next month.
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
by Arpita Dutt
Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.
Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
by Zacks Equity Research
Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.
Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.
Model N (MODN) Q1 Loss Narrower than Expected, Guides Well
by Zacks Equity Research
Model N, Inc. (MODN) reported a loss (excluding stock based compensation) of 21 cents per share in first-quarter 2017, which was narrower than the Zacks Consensus Estimate.
Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.
Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study
by Zacks Equity Research
Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .
Novartis (NVS) Votubia Gets EU Approval for Label Expansion
by Zacks Equity Research
Novartis (NVS) wins EU approval for label expansion of Votubia in refractory partial-onset seizures in patients with tuberous sclerosis complex.
GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.
Momenta Says District of Delaware Invalidates Teva's MS Drug
by Zacks Equity Research
Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .
Drug Stocks Rally on Trump Meet with Pharma Bigwigs
by Arpita Dutt
Pharma and biotech stocks were up as President Trump discussed a speedier drug approval process, lower regulations and corporate tax reforms.
Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting
by Madeleine Johnson
Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.
Biotech Stocks Gain on Latest Trump Drug Price Statements
by Ryan McQueeney
President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.
Incyte and Calithera Enter into Deal for Oncology Candidate
by Zacks Equity Research
Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.
Amgen Wins Favorable CHMP Opinion for Humira Biosimilar
by Zacks Equity Research
Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.
Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
by Zacks Equity Research
Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).
Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon
by Zacks Equity Research
Novartis' (NVS) fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. The company has been facing challenging conditions for the past few quarters.